SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf
of Investors of MAP Pharmaceuticals, Inc. - MAPP
NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Pomerantz
Grossman Hufford Dahlstrom & Gross LLP is investigating claims
on behalf of investors of MAP Pharmaceuticals, Inc. ("MAP
Pharmaceuticals" or the "Company") (NASDAQ: MAPP) (ISIN:
US56509R1086) (CUSIP: 56509R108) concerning the proposed
acquisition of MAP Pharmaceuticals by Allergan, Inc. in a
transaction valued at approximately $985
million in cash.
The investigation concerns whether the MAP Pharmaceuticals
directors are breaching their fiduciary duties by failing to
adequately shop the Company and maximize shareholder value.
Under the terms of the agreement, MAP Pharmaceuticals shareholders
will be entitled to receive $25.00
per share in cash for each share of MAP Pharmaceuticals common
stock. However, at least one analyst noted that the offered
price undervalues MAP Pharmaceuticals' new migraine treatment drug
Levadex.
MAP Pharmaceuticals shareholders seeking more information about
this acquisition are advised to contact Robert Willoughby at rswilloughby@pomlaw.com or
212-661-1100 or 888-476-6529, ext. 237.
The firm is also investigating actions on behalf of shareholders
for the following companies: Arbitron Inc., Net1 Ueps Technologies,
Inc., Hi-Crush Partners LP, Intermec, Inc., SandRidge Energy, Inc.,
Abiomed, Inc., Universal Technical Institute, and Clearwire
Corporation, Ameristar Casinos, Inc. K-Swiss, Inc., Neptune
Technologies Bioressources, Inc. Telanetix, Inc.
The Pomerantz Firm, with offices in New York, Chicago and San
Diego, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 75 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of defrauded
investors. See www.pomerantzlaw.com.
SOURCE Pomerantz Grossman Hufford
Dahlstrom & Gross LLP